High-sensitivity Troponin
[High-sensitivity Troponin]
EPTIS factsheet 142542 | Last revision 2024-05-21 | URL: https://www.eptis.bam.de/pts142542 https://www.eptis.bam.de/pts142542
| PT provider | ||||||||||
| PT provider | Weqas Weqas | |||||||||
| Based in | United Kingdom | |||||||||
| Language(s) | ||||||||||
| Remarks | High sensitivity cardiac Troponin (hs-cTn) T and I have replaced standard Troponin assays, myoglobin and Creatine kinase – MB as the preferred markers of myocardial injury. NICE diagnostic guidance – [DG40], High sensitivity troponin tests for the early rule out of NSTEMI, published in August 2020 recommended a number of hs-cTn methods that could be used for the early rule out of non-ST-segment elevation myocardial infarction (NSTEMI) in people presenting to an emergency department with chest pain and suspected acute coronary syndrome. The hsTropnin EQA programme is available as serum samples. Three liquid human serum samples are distributed monthly, with a minimum of 36 samples distributed over the year covering a wide clinical range. The samples consist of endogenous samples from patients along with a panel of linearly related samples produced from donations from healthy volunteers spiked with Cardiac Troponin. The programme includes samples at clinically relevant ranges at or near the limit of detection, samples at the 99th centiles, thresholds for early rule out and at high hs-cTn concentrations seen in myocardial infarction. The samples are distributed on a number of occasions over the year which allows for the assessment of the laboratory’s and method’s performance, including linearity, bias, within and between batch imprecision. Key Features: - Includes challenging samples at limits of detection and diagnostic “99th centile” for hs-cTnT and hs-cTnl. - Liquid human serum samples require no pre-analytical preparation. - Linearly related panel covering a clinically relevant range. For more information: https://www.weqas.com/services/eqa/hs-troponin/ or contact@weqas.com | |||||||||
| Keywords | ||||||||||
| Product groups |
Health care / medical devices
|
|||||||||
| Testing fields |
Medical analysis
|
|||||||||
| Technical details | ||||||||||
|
||||||||||
| Aims of the PT scheme | ||||||||||
| Target group of participants | The Programme aims to assess the performance of organisations utilising biochemical cardiac markers to aid in the diagnosis of acute coronary syndrome (ACS) and cardiac ischaemia. | |||||||||
| Linked to specific legislation / standards | Accreditation by UKAS on the basis of ISO/IEC 17043 | |||||||||
| Additional, subsidiary aims | validation of testing methods | |||||||||
| Number of participants | ||||||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043 |
|||||||||
| Operation is commissioned / requested by | ||||||||||
| Fees and frequency | ||||||||||
| Participation fee | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||
| Regularly operated | Yes (Frequency: Monthly. Samples: 3 x 1.0mL.) | |||||||||
| Year of first operation | 2005 | |||||||||
| Contact details of the PT provider | ||||||||||
| Provider | Contact person | |||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.